about
KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic AdenocarcinomaPancreatic ductal adenocarcinoma in BRCA2 mutation carriersGemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.Molecular packing and magnetic properties of lithium naphthalocyanine crystals: hollow channels enabling permeability and paramagnetic sensitivity to molecular oxygen.Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.[Severe thrombopenia as single sign of hemophagocytosis in a patient with cirrhosis and lethal infection of ascitis fluid by Escherichia coli].Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.Design of a variable temperature scanning force microscope.Frozen sectioning of the pancreatic cut surface during resection of intraductal papillary mucinous neoplasms of the pancreas is useful and reliable: a prospective evaluation.Proteomic assessment of markers for malignancy in the mucus of intraductal papillary mucinous neoplasms of the pancreas.Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).Intraductal papillary and mucinous pancreatic tumour: a new extracolonic tumour in familial adenomatous polyposis.Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie DigestivGemcitabine in elderly patients with advanced pancreatic cancerClinical and genetic studies of Birt-Hogg-Dubé syndrome.Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.Risk of pancreatic adenocarcinoma in chronic pancreatitisA randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trialPEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancerPrognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP).Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors.Technique of pancreatic cyst aspiration.Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.Prognostic factors for resectable pancreatic adenocarcinoma.Sunitinib in pancreatic neuroendocrine tumors.New treatment options with cytotoxic agents in neuroendocrine tumours.Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.Acute pancreatitis during pregnancy: a review.Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.State of the art and future directions of pancreatic ductal adenocarcinoma therapy.Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease.Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database.
P50
Q27853365-7A244897-8168-41F0-B3D6-59336898BA9DQ28075505-FE8735AF-E02B-4C68-9234-B5F1698CBA80Q30317428-98645AC3-13ED-4625-A647-67CEDAECED1BQ30486184-CCE7F0F6-B509-4725-A083-0E3D565B7BCBQ33341477-72A100C5-C69E-449D-B76E-6ABFE3F75D9FQ33378108-BA641FD1-9FA3-4193-9E1A-603B8F5CDA64Q33389018-9E825B74-2407-45DB-98AE-1713DE92F281Q33425869-240C9EC7-87FE-4150-BCB2-2FF9CB28DC80Q33432931-1B46D5E0-D1AF-4704-B072-34730AC3F6EAQ33440884-513307FE-EDCC-40AD-8133-DC9359576DD1Q33499469-5F9E8F1E-9254-4F46-9F44-232F991C7925Q33991839-6183D1FF-2E0F-44E7-A008-FDD29E902452Q34072811-F63E85BB-6830-4E7D-A73B-BA8B8C74587FQ34308370-44F60626-09D0-4FCA-ADCB-C46C7E357610Q34526116-983EF5BD-31F0-4D7B-A10C-0B9B732250DFQ34557866-D84C264F-6B59-4BFC-A0CC-EE4A8771C9ECQ34600909-4F02A079-D87D-4824-BA10-A22ED5DA9429Q34665199-F6E99ABD-89B2-4836-93C2-B62A2D3DD806Q35185110-5F43EDAE-DBFC-47BA-B301-3116396EAD98Q35559819-DE686C22-B264-49D6-BFB5-0FAF2C3BDFF2Q35595090-741D0C3A-2E3F-4268-85A3-F9A9FAFEF979Q35595218-35F03B41-4025-4050-ADCD-595A62423B9BQ35892017-05003471-8276-43CA-BE12-6A795CDE313DQ36131174-ABB6D0C7-1F0B-4F56-9D62-21062C0331EFQ36797283-CA370B48-2196-4DBB-8507-88A4CA1D98D4Q37151116-2FCDA481-9802-409C-A6DA-71D03EBBF0DAQ37354637-87728AD1-89EA-40B7-8E92-E370B52D22FCQ37380280-314A7F94-3E1E-479F-85A2-41144006504CQ37709139-093F3061-DF4C-476C-B336-4756197FDADEQ37910465-E4542AAF-9AA8-47FB-AB1A-7583D353EAB7Q37933704-9F71A935-E3A1-484B-B989-722EA3A52114Q38015764-AF18A33B-2258-4372-88A3-411FC1A626B3Q38036570-B41D677C-C522-4A01-8CFA-3ADA269E4143Q38053855-EFD78CA1-2BF3-4021-884F-AF91B6095CA8Q38172748-AD2F8856-DB18-4807-B323-D8F6F519B146Q38254413-654CE1E4-9FCC-46ED-9056-9ADE31619B23Q38393038-FADD770A-57C0-4EBB-AE4E-498AAF3C9592Q38572208-49F6F81C-9A4C-4D7B-9EC6-710D24888C71Q38794106-E50BAAD4-2D38-48B4-BB1A-45F0714B9E72Q38804749-EAFAC853-4E99-41AD-99FC-1AC81EA71F9D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pascal Hammel
@ast
Pascal Hammel
@en
Pascal Hammel
@es
Pascal Hammel
@nl
Pascal Hammel
@sl
type
label
Pascal Hammel
@ast
Pascal Hammel
@en
Pascal Hammel
@es
Pascal Hammel
@nl
Pascal Hammel
@sl
prefLabel
Pascal Hammel
@ast
Pascal Hammel
@en
Pascal Hammel
@es
Pascal Hammel
@nl
Pascal Hammel
@sl
P106
P21
P31
P496
0000-0002-4630-4996
P569
2000-01-01T00:00:00Z